ClinConnect ClinConnect Logo
Search / Trial NCT01196689

Pharmacokinetics in Adolescents

Launched by ASTRAZENECA · Sep 6, 2010

Trial Information

Current as of May 29, 2025

Completed

Keywords

Pharmacokinetics Azd1981 Asthma

ClinConnect Summary

An open, single centre, phase I study in male adolescents with asthma, aged 12 to 17 years, to assess pharmacokinetics of orally administered AZD1981 tablets 100 mg twice daily for 61/2 days.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • Provision of informed consent prior to any study specific procedures
  • A minimum of 6 months documented history of asthma
  • Be a non-smoker or ex-smoker who has stopped smoking for \>6 months prior to Visit 1 (pre-entry)
  • Exclusion Criteria:
  • Any clinically significant disease or disorder which, in the opinion of the investigator, may either put the patient at risk because of participation in the study, or influence the result of the study, or the patient's ability to participate
  • Any clinically relevant abnormal findings in phys.examination, clinical chemistry, haematology, urinalysis, vital signs, or ECG at baseline which, in the opinion of the investigator, may put the patient at risk because of his participation in the study

About Astrazeneca

AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Uppsala, , Sweden

Patients applied

0 patients applied

Trial Officials

Christer Hultquist

Study Director

AstraZeneca

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials